Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

FCRL regulation in innate-like B cells.

Davis RS.

Ann N Y Acad Sci. 2015 Dec;1362:110-6. doi: 10.1111/nyas.12771. Review.

2.

Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.

Innis-Shelton RD, Davis RS, Lamb L, Mineishi S.

Leuk Lymphoma. 2015 Jun;56(6):1626-35. doi: 10.3109/10428194.2014.974041. Review.

PMID:
25308292
3.

FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation.

Li FJ, Schreeder DM, Li R, Wu J, Davis RS.

Eur J Immunol. 2013 Nov;43(11):2980-92. doi: 10.1002/eji.201243068.

4.

FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling.

Zhu Z, Li R, Li H, Zhou T, Davis RS.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1282-90. doi: 10.1073/pnas.1215156110.

5.

FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling.

Sohn HW, Krueger PD, Davis RS, Pierce SK.

Blood. 2011 Dec 8;118(24):6332-41. doi: 10.1182/blood-2011-05-353102.

6.

Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia.

Li FJ, Kubagawa Y, McCollum MK, Wilson L, Motohashi T, Bertoli LF, Barton JC, Barnes S, Davis RS, Kubagawa H.

Blood. 2011 Nov 3;118(18):4902-9. doi: 10.1182/blood-2011-04-350793.

7.

Unraveling the molecular pathogenesis of chronic lymphocytic leukemia: dissecting a microRNA regulatory network.

Allendorf DJ, Davis RS.

JAMA. 2011 Jan 5;305(1):95-7. doi: 10.1001/jama.2010.1940. No abstract available.

PMID:
21205973
8.

FCRLA is a resident endoplasmic reticulum protein that associates with intracellular Igs, IgM, IgG and IgA.

Santiago T, Kulemzin SV, Reshetnikova ES, Chikaev NA, Volkova OY, Mechetina LV, Zhao M, Davis RS, Taranin AV, Najakshin AM, Hendershot LM, Burrows PD.

Int Immunol. 2011 Jan;23(1):43-53. doi: 10.1093/intimm/dxq456.

9.

FcR-like 2 Inhibition of B cell receptor-mediated activation of B cells.

Jackson TA, Haga CL, Ehrhardt GR, Davis RS, Cooper MD.

J Immunol. 2010 Dec 15;185(12):7405-12. doi: 10.4049/jimmunol.1002305.

10.

Cutting edge: FcR-like 6 is an MHC class II receptor.

Schreeder DM, Cannon JP, Wu J, Li R, Shakhmatov MA, Davis RS.

J Immunol. 2010 Jul 1;185(1):23-7. doi: 10.4049/jimmunol.1000832.

11.

Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin.

Campbell JA, Davis RS, Lilly LM, Fremont DH, French AR, Carayannopoulos LN.

J Immunol. 2010 Jul 1;185(1):28-32. doi: 10.4049/jimmunol.1000240.

12.

The FCRL3-169CT promoter single-nucleotide polymorphism, which is associated with systemic lupus erythematosus in a Japanese population, predicts expression of receptor protein on CD19+ B cells.

Gibson AW, Li FJ, Wu J, Edberg JC, Su K, Cafardi J, Wiener H, Tiwari H, Kimberly RP, Davis RS.

Arthritis Rheum. 2009 Nov;60(11):3510-2. doi: 10.1002/art.24915. No abstract available.

13.

Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5.

Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T.

Cancer Cell. 2009 Aug 4;16(2):161-71. doi: 10.1016/j.ccr.2009.05.018.

14.

FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia.

Schreeder DM, Pan J, Li FJ, Vivier E, Davis RS.

Eur J Immunol. 2008 Nov;38(11):3159-66. doi: 10.1002/eji.200838516.

15.

FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.

Li FJ, Ding S, Pan J, Shakhmatov MA, Kashentseva E, Wu J, Li Y, Soong SJ, Chiorazzi N, Davis RS.

Blood. 2008 Jul 1;112(1):179-87. doi: 10.1182/blood-2008-01-131359.

16.

IgEb immune complexes activate macrophages through FcgammaRIV binding.

Hirano M, Davis RS, Fine WD, Nakamura S, Shimizu K, Yagi H, Kato K, Stephan RP, Cooper MD.

Nat Immunol. 2007 Jul;8(7):762-71.

PMID:
17558411
17.

Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment.

Haga CL, Ehrhardt GR, Boohaker RJ, Davis RS, Cooper MD.

Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9770-5.

18.

Fc receptor-like proteins (FCRL): immunomodulators of B cell function.

Ehrhardt GR, Leu CM, Zhang S, Aksu G, Jackson T, Haga C, Hsu JT, Schreeder DM, Davis RS, Cooper MD.

Adv Exp Med Biol. 2007;596:155-62. Review. No abstract available.

PMID:
17338184
19.

Fc receptor-like molecules.

Davis RS.

Annu Rev Immunol. 2007;25:525-60. Review.

PMID:
17201682
20.

Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells.

Won WJ, Foote JB, Odom MR, Pan J, Kearney JF, Davis RS.

J Immunol. 2006 Nov 15;177(10):6815-23.

Supplemental Content

Loading ...
Support Center